



Platform CRM – TMC: **a linked procedure for companion reimbursement**

Anouk Waeytens


National Institute for Health and Disability Insurance Belgium

impact of personalised medicine on the Belgian health care system



COVER TIME MAGAZINE, 28 MAY 2001

impact of personalised medicine on the Belgian health care system



impact of personalised medicine on the Belgian health care system

reimbursement of medicines (CRM)

versus

reimbursements of acts/diagnostic tests (TMC)

- ▣ different commission
- ▣ different timelines
- ▣ different budget
- ▣ within NIHDI: different departments



□ Medicines:

CRM

Minister

MD

6 months + suspensions

□ Tests:

□ first: WG Clinical Biology, then:

TMC

Medico-
mut

CBC

Ins
Com

Minister

RD

minimum 18 months

access to personalized medicine

→ health care reimbursement procedures should be adapted to achieve a simultaneous reimbursement start for treatment and test

→ Challenge:

- ▣ **2 different technologies/processes/expertise**
- ▣ **keep up with quick technological evolution**
- ▣ **flexibility**

Platform Companion Diagnostics

- launched 19/1/2016
- members:
 - representatives of TMC and CRM (Bureau)
 - laboratories, clinicians, insurers, WIV-ISP, KCE, NIHDI, ComPerMed
 - invitees (HealthData, Cancer Register,...)
 - conflict of interest, confidentiality
- secretariat:
 - Catherine Adriaens (pharmaceutical dept)
 - **CDX@riziv.fgov.be**



reimbursement of personalised medicine: permanent mixed working group CRM – TMC

- tasks:
 - advise to both CRM and TMC
 - new nomenclature
 - modifications of existing nomenclature (link drug)
 - ad hoc expertise dossiers (CRM-TMC)
 - e.g. Tagrisso (CRM)
- communication ComPerMed

current projects for new nomenclature (art33bis)

1. Novel testing technologies, e.g. NGS:
convention
2. Validated molecular biology technologies, e.g. PCR:
linked reimbursement procedure
simultaneous reimbursement drug-test

package drug – test: single short HTA

- **Proposal:** the Commission for Reimbursement of Medicines (CRM) advises the Minister on the reimbursement of the drug and the “companion” tests

advise: platform CDx

single Ministerial Decree

Nomenclature for tests:
stays competence of TMC

- Concept:

- article 33ter:


- new “generic” nomenclature codes for tests linked to a drug
 - defined by TMC
 - published by royal decree

- chapter “VIII”:

- “personalised” drugs
 - + annex with “companion” tests

if the Minister decides to reimburse the drug, the marker will be added to the list by the same Ministerial Decree

Nomenclature: art. 33ter Drugs: Chapter VIII



Personalised medicine: linked reimbursement procedure



Personalised medicine: linked reimbursement procedure

